We report a case of fatal congenital cytomegalovirus (CMV) disease in a 695 gm, 29 weeks estimated gestational age premature infant. The newborn presented with hydrops fetalis, an unusual presentation of congenital CMV infection. In spite of ganciclovir therapy, the infant succumbed to his illness. Autopsy findings revealed the presence of widespread CMV disease, including pneumonitis, enteritis, and myocarditis. Congenital CMV infection should be considered in the differential diagnosis of hydrops fetalis.
INTRODUCTION
Given the diversity of potential etiologies, 1 the investigation of nonimmune hydrops fetalis requires a multidisciplinary approach. Infectious pathogens acquired in utero represent an important category of the identifiable causes of hydrops fetalis 2 among which parvovirus B19 is the most common agent. 3 Among the other viral etiologies of hydrops fetalis, cytomegalovirus (CMV) infection, although uncommon, is important to identify, since specific antiviral therapy is available. 4 We report a case of congenital CMV infection presenting as fetal hydrops, in an infant who died of severe pneumonitis, despite the use of ganciclovir therapy.
CASE REPORT
The patient was a male infant born at 29 weeks gestation with a birth weight of 695 g. The infant was the third pregnancy of a 21-year-old Caucasian with a history of hypothyroidism and alcohol and cocaine abuse. She had one prior uneventful term pregnancy and one spontaneous abortion. She had received very little antenatal care and presented with a pregnancy that was estimated, by dates, to be 28 weeks estimated gestational age (EGA) with possible preterm labor. An ultrasound confirmed a singleton pregnancy with oligohydraminos, pericardial effusion and ascites. Antenatal serologic testing performed for varicella-zoster virus, toxoplasmosis, syphilis, rubella, herpes simplex virus, and HIV were negative. Maternal IgG, but not IgM, antibodies to parvovirus B19, and cytomegalovirus were detected. Antiplatelet antibodies, ANCA, and ANA antibodies were all negative. Fetal echocardiogram revealed a moderate pericardial effusion and a structurally normal heart. A fetal MRI performed to better evaluate the fetal hydrops ( Figure 1 ) revealed oligohydramnios, cardiomegaly, pericardial effusion, and ascites with hepatosplenomegaly, confirming the diagnosis. A peri-umbilical blood sample revealed a white blood cell count of 2900/mm 3 , a hemoglobin concentration of 8.6 g/dl, and a platelet count of 16,000/mm 3 . While a fetal blood transfusion was being attempted to correct the anemia fetal bradycardia ensued, necessitating emergent caesarean section.
The infants Apgars were 1, 1, 2, and 4 at 1, 5, 10, and 15 min, respectively. He was resuscitated with high inflation pressures, 20 ml/kg of normal saline and sodium bicarbonate. Physical examination on admission was remarkable for symmetrical IUGR (<10th centile), based on the EGA of 28 weeks. Since the estimation of gestational age was based on dates of a woman who had very little prenatal care, the possibility of a younger gestational age (e.g., 25 to 26 weeks) could not definitively be excluded. The initial physical exam was also remarkable for severe hepatosplenomegaly, and pallor. The initial CBC had a hematocrit of 14%, platelets of 29 and absolute neutrophil count of 800. Chest X-ray was consistent with respiratory distress syndrome and an enlarged cardiac silhouette. Echocardiography performed on day of life (DOL) 2 to evaluate the cardiomegaly revealed the presence of a small to moderate pericardial effusion, structurally normal heart, and normal ventricular function. The infant's respiratory status initially improved after surfactant and high-frequency oscillation, and he was extubated by DOL 2.
A clinical diagnosis of congenital CMV was entertained because of the physical findings, and a work-up was instituted. Histopathological analysis of the placenta ( Figure 2 ) revealed plasmacytic villitis consistent with CMV infection, confirmed by immunohistochemistry and in-situ hybridization. Head ultrasound examination revealed periventricular calcifications. The infant also had evidence of hepatitis. The peak AST was 248, and the ALT was 33 on day 2. The direct bilirubin was 3.2 as early as DOL 2, and gradually rose to greater than 8 by DOL 25. The infant's clinical condition deteriorated during the second week of life, with the development of pneumonitis and progression of hepatic dysfunction. Thrombocytopenia persisted, and was refractory to platelet transfusions. A urine culture obtained during the first week of life was positive for CMV by shell-vial assay, confirming CMV as the likely cause of fetal hydrops. Ganciclovir (12 mg/kg/day) was begun on DOL 14. The infant's condition continued to deteriorate, and on DOL 25, he died. Autopsy identified CMV inclusions in the lungs, in the gastric and small bowel mucosa, and in the thyroid, kidneys, adrenal glands, and myocardium ( Figure 3 ).
DISCUSSION
Hydrops fetalis may be caused by a variety of hematologic and immune-mediated mechanisms. 1 Among the immune-mediated mechanisms, Rh-incompatibility with resulting hemolytic disease has become rare today. Other etiologies include cardiac defects, arrhythmias, twin-to-twin transfusion syndrome, chromosomal abnormalities, infectious agents, inborn errors of metabolism, alpha thalassemia, laryngeal atresia, and fetomaternal hemorrhage. 1 In up to one third of the cases, the etiology is unknown. Among the infectious agents, which have been associated with nonimmune hydrops fetalis, parvovirus B19 3 is the most common, although CMV, herpes simplex virus, Toxoplasma gondii, adenovirus, enterovirus, and treponoma pallidum have all been implicated. 2 We document here a case of congenital CMV infection presenting with fetal hydrops.
For the infant described in this case, the pathogenesis of fetal hydrops secondary to CMV infection acquired in utero was most likely multifactorial. Fetal anemia, secondary to altered erthyropoiesis, may likely represent the consequence of dissemination of CMV to fetal liver and spleen, the predominant hematopoietic organs in utero. In addition, CMV myocarditis was noted ( Figure 3 ) on post mortem, and may have contributed to heart failure. A similar mechanism of injury has been postulated for parvovivrus B19, which is capable of infecting cardiac myocytes in addition to erythroid precursors. 5 CMV is an unusual cause of acquired myocarditis in normal children, 6 but cardiac involvement has been previously described in a fatal case of congenital disease in a newborn infant. 7 Although congenital CMV infection is common, affecting up to 2% of all newborns, fetal hydrops as a complication of congenital CMV infection is rare. [8] [9] [10] Congenital infections with CMV may occur either in women with primary infection during pregnancy or in women with preconceptual immunity who have either reactivation of a latent infection, or re-infection with a heterologous strain of virus. 11 Since our infant's mother was CMV IgG positive but CMV IgM negative, CMV infection occurred most likely in the infant as a result of reactivation of the virus or reinfection with a new strain. Transmission of CMV to the fetus in the face of preconceptual maternal immunity has been increasingly recognized as a cause of symptomatic disease in newborns. Although most congenital infections that occur in the setting of preconceptual immunity are asymptomatic, such infections still appear to carry a risk of neurodevelopmental sequelae, including sensorineural deafness. 12 Our patient succumbed to severe, multiorgan CMV disease even in the face of ganciclovir therapy. Extreme prematurity, inadequate transfer of protective maternal antibody, and possibly a high viral load may have all contributed to a fulminant disease course. Unfortunately, we were not able to quantify the viral load in the infant, although the use of sensitive polymerase chain reaction (PCR) assays may prove to be useful in the clinical management of congenitally infected infants. 13 In an animal model of antiviral therapy of CMV infection, the magnitude of the reduction of viral load by PCR has proven to be a useful marker of response to treatment, 14 underscoring the potential usefulness of these assays in monitoring infants.
Once the diagnosis of CMV infection was confirmed in the patient described in this case report, antiviral therapy was commenced, with ganciclovir. Therapy with ganciclovir has been evaluated by an NIH-sponsored Collaborative Antiviral Study Group (CASG) trial in infants with congenital CMV infection and central nervous system (CNS) involvement, to examine whether therapy confers any protection against CMV-induced hearing loss. 15 . This study has indicated that antiviral therapy in symptomatic newborns with congenital infection and CNS involvement reduces the risk of sensorineural deafness. 15 The role of ganciclovir in the acute management of other forms of severe CMV disease in newborns is not clearly established. However, as our case illustrates, congenital CMV infection can be a life-threatening disease process. The use of ganciclovir therapy for congenital CMV infection and disease has generally been reported to be safe and well-tolerated, and has appeared to be useful in ameliorating the severity of focal, endorgan disease, including pneumonitis and hepatitis. [16] [17] [18] [19] [20] [21] [22] [23] We therefore strongly recommend that ganciclovir therapy should be used in the setting of life-threatening CMV infection, particularly when end-organ disease is documented by culture or histopathologic analysis. Ganciclovir therapy was initiated relatively late in the course of the infant described in this report, in part because the role of CMV as an etiologic agent for the fetal hydrops was not suspected until the infant was several days of age, and had been clearly demonstrated to have other stigmata of congenital CMV infection, including hepatic, hematologic, and neurologic disease. This case illustrates the importance of obtaining appropriate studies for rapid diagnosis of congenital CMV infection in newborns with unexplained fetal hydrops, in order to direct timely intervention with antiviral therapy. Development and implementation of screening programs for identification of congenital CMV infection, potentially using newborn blood spots obtained at the time of the metabolic screen, could aid in identifying congenitally infected infants who, though asymptomatic, might benefit from careful neurodevelopmental monitoring and, possibly, antiviral therapy to prevent sensorineural deafness. 24 The ultimate control of CMV disease in newborns, however, will most likely depend upon the development of an effective vaccine, which, if administered to young women prior to the onset of their child-bearing years, could reduce the burden associated with this important public health problem. 25, 26 
